Amneal Pharmaceuticals Inc. has released its 2024 Responsible Business Report, detailing progress in environmental, social, and governance $(ESG)$ initiatives. The report outlines efforts to enhance healthcare access, promote environmental sustainability, and support workforce development. Key highlights include the introduction of a new ESG framework structured around societal impact, environmental impact, and people & practices. In 2024, Amneal filled over 162 million prescriptions in the U.S., launched 22 new generic products, and addressed drug shortages by producing over 10 critical injectable medicines. Environmental efforts included transitioning a manufacturing facility in India from coal to biomass, reducing CO₂ emissions by 1,600 tons annually, and supporting tree planting initiatives. The company also launched a global talent development framework and reported an increase in employee engagement. The full report aligns with global standards and is available on Amneal's website.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.